Robalzotan AstraZeneca.

H A, Mucke

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2001

Data sources: Europe PubMed Central

Robalzotan AstraZeneca.

descriptionPublicationkeyboard_double_arrow_right Article 19 Apr 2001 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 1 (issn: 1472-4472,

Copyright policy )

Authors: H A, Mucke;

pmid: 11249580

Robalzotan AstraZeneca.

- Summary
- Subjects
- Metrics

Abstract

AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a predicted launch date of 2005 [384880].

Keywords

Migraine Disorders, Drugs, Investigational, Anxiety, Patents as Topic, Structure-Activity Relationship, Anti-Anxiety Agents, Animals, Humans, Benzopyrans, Serotonin Antagonists

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average